New Report Says Extra Than Half of CBD Merchandise Are Mislabeled

The opinions of entrepreneurs’ contributors are their own.

As cannabis products become mainstream, there is a lot of blind trust when it comes to buying edibles, topicals, oils, and more. Just because recreational use is legal in 19 states plus Washington DC and Guam doesn’t mean all facets of the industry are on the rise, especially when it comes to CBD and labeling.

Leafreport has tested more than 200 CBD products for the accuracy of the labels this year and has found many discrepancies in terms of strength, type of CBD used, and even CBD in the product.

RELATED: The Majority of Delta 8 THC Products in the U.S. Are Incorrectly Labeled

The results of the report

Leafreport spanned 111 different brands and tested 35 CBD oils, 40 topical, 40 edible, 22 beverage, and 29 coffee and tea products by third parties. At least 60% of the products tested did not match the CBD strength promised on the label. The 40% that passed was within 10% of the promised CBD strength.

Twenty-eight percent of products were rated F for CBD levels that were more than 30% off the label, with drinks (again) being the worst culprits. Only 18% of these were labeled and two had no CBD at all. And it found that lesser-known brands performed better than well-known brands on tests, raising many questions about branding and loyalty in the cannabis space.

RELATED: A Majority of CBD Pet Products Are Wrong

Medical experts weigh in

Several experts commented on the new report, most saying it was just evidence that more needs to be done with quality control and regulations on hemp CBD products.

“CBD is effective for many ailments; this is widely accepted, ”says naturopathic doctor Dr. Carlie Bell-Biggins to Leafreport. “However, the correct dosage is still unclear, especially since the individual variations within the endocannabinoid system are unique from person to person. Incorrectly labeled products only make this problem worse. “

“In the US, the FDA is still reviewing data, particularly on the safety, possible side effects, and benefits of CBD. It’s a frustratingly slow process, hampered by the fact that too many researchers stay away from cannabinoids because of the regulatory gray area, ”says Zora DeGrandpre. “This problem is exacerbated by companies that fail to follow basic quality control aspects – selling products that contain the stated amount of CBD and testing for various impurities. These companies give CBD a bad name. “

With the increase in CBD use across the country, it is high time the industry and federal agencies are on the same page to ensure that every product is safe for consumption.